Yayın:
Brentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study

Sadeleştirilmiş öğe sayfası
dc.contributor.authorAteşoğlu, Elif Birtaş
dc.contributor.authorMurat Özbalak
dc.contributor.authorMustafa Pehlıvan
dc.contributor.authorBirol Yıldız
dc.contributor.authorAnt Uzay
dc.contributor.authorTuğçe Nur Yiğenoğlu
dc.contributor.authorTuğrul Elverdi
dc.contributor.authorLeylagül Kaynar
dc.contributor.authorOrhan Ayyıldız
dc.contributor.authorİpek Yönal Hindilerden
dc.contributor.authorHasan Sami Göksoy
dc.contributor.authorŞebnem İzmir Güner
dc.contributor.authorAhmet Kürşad Güneş
dc.contributor.authorMehmet Sönmez
dc.contributor.authorMeltem Kurt Yüksel
dc.contributor.authorSinem Civriz Bozdağ
dc.contributor.authorZübeyde Nur Özkurt
dc.contributor.authorTayfur Toptaş
dc.contributor.authorMehmet Hilmi Doğu
dc.contributor.authorOzan Salim
dc.contributor.authorGüray Saydam
dc.contributor.authorİrfan Yavaşoğlu
dc.contributor.authorMeltem Aylı
dc.contributor.authorGülsüm Özet
dc.contributor.authorMurat Albayrak
dc.contributor.authorElif Birtaş Ateşoğlu
dc.contributor.authorSelami Koçak Toprak
dc.contributor.authorRahşan Yıldırım
dc.contributor.authorÖzgür Mehtap
dc.contributor.authorSevgi Kalayoğlu Beşışık
dc.contributor.authorMeliha Nalçacı
dc.contributor.authorFevzi Altuntaş
dc.contributor.authorBurhan Ferhanoğlu
dc.contributor.orcid0000-0002-6759-1939
dc.contributor.orcid0000-0002-3040-4052
dc.contributor.orcid0000-0002-6692-085X
dc.contributor.orcid0000-0001-8920-6467
dc.contributor.orcid0000-0003-1381-4188
dc.contributor.orcid0000-0001-9962-8882
dc.contributor.orcid0000-0001-9496-5353
dc.contributor.orcid0000-0002-2035-9462
dc.contributor.orcid0000-0003-3020-850X
dc.contributor.orcid0000-0003-3795-3502
dc.contributor.orcid0000-0002-6326-9424
dc.contributor.orcid0000-0001-5522-8342
dc.contributor.orcid0000-0002-2176-4371
dc.contributor.orcid0000-0003-0369-299X
dc.contributor.orcid0000-0001-8359-7794
dc.contributor.orcid0000-0001-9834-6058
dc.contributor.orcid0000-0002-2690-8581
dc.contributor.orcid0000-0001-7237-2637
dc.contributor.orcid0000-0001-6687-0189
dc.contributor.orcid0000-0001-8646-1673
dc.contributor.orcid0000-0003-1703-2175
dc.contributor.orcid0000-0001-5766-5642
dc.contributor.orcid0000-0003-2658-5978
dc.contributor.orcid0000-0003-4025-741X
dc.contributor.orcid0000-0002-2596-4493
dc.contributor.orcid0000-0001-7717-5827
dc.contributor.orcid0000-0002-5717-3936
dc.contributor.orcid0000-0002-5603-1178
dc.contributor.orcid0000-0002-9310-1278
dc.contributor.orcid0000-0002-2555-5024
dc.contributor.orcid0000-0001-6872-3780
dc.contributor.orcid0000-0002-4257-549X
dc.date.accessioned2025-11-13T09:47:04Z
dc.date.issued2021-06-25
dc.identifier.doihttps://doi.org/10.1002/hon.2897
dc.identifier.endpage505
dc.identifier.issn0278-0232
dc.identifier.issue4
dc.identifier.openalexW3174496931
dc.identifier.startpage498
dc.identifier.urihttps://hdl.handle.net/11421/2181
dc.identifier.urihttps://doi.org/10.1002/hon.2897
dc.identifier.volume39
dc.language.isoen
dc.relation.ispartofHematological Oncology
dc.rightsrestrictedAccess
dc.subjectMedicine
dc.subjectBrentuximab vedotin
dc.subjectInternal medicine
dc.subjectAutologous stem-cell transplantation
dc.subjectNeutropenia
dc.subjectSalvage therapy
dc.subjectTransplantation
dc.subjectSurgery
dc.subjectRegimen
dc.subjectAdverse effect
dc.subjectFebrile neutropenia
dc.subjectLymphoma
dc.subjectOncology
dc.subjectChemotherapy
dc.subjectHodgkin lymphoma
dc.subject.sdg3
dc.titleBrentuximab vedotin consolidation therapy after autologous stem‐cell transplantation in patients with high‐risk Hodgkin lymphoma: Multicenter retrospective study
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5035163221

Dosyalar

Koleksiyonlar

Publications